Last updated: August 7, 2026
Pretomanid is a specialized tuberculosis drug with high clinical value but limited standalone revenue potential. FDA approval covers pretomanid only as part of the BPaL regimen with bedaquiline and linezolid for adults with highly drug-resistant pulmonary tuberculosis. Its commercial market is constrained by the small diagnosed patient population, public-sector procurement, low-income-country pricing, and the need to use the drug in combination therapy. Viatris commercializes Dovprela in the United States, while the TB Alliance controls the underlying development and licensing framework. Separate pretomanid revenue is not publicly disclosed by Viatris, making the product’s financial trajectory impossible to isolate from company-level reporting. [1-4]
What is pretomanid and how is it used?
Pretomanid is a nitroimidazo-oxazine antibacterial developed for drug-resistant tuberculosis. The FDA approved Dovprela, a 200-mg tablet, on August 14, 2019, under NDA 212862. The approved regimen combines pretomanid with bedaquiline and linezolid for adults with extensively drug-resistant pulmonary tuberculosis, treatment-intolerant or nonresponsive multidrug-resistant pulmonary tuberculosis, or other qualifying resistant forms of pulmonary TB. [1]
The drug is not approved as monotherapy. Its commercial demand therefore depends on procurement and adoption of the full BPaL or BPaLM regimen.
| Item |
Pretomanid status |
| Active ingredient |
Pretomanid |
| Brand |
Dovprela |
| Strength |
200 mg tablet |
| FDA approval |
August 14, 2019 |
| FDA application |
NDA 212862 |
| Approved use |
Combination treatment for qualifying drug-resistant pulmonary TB |
| Core regimen |
Bedaquiline, pretomanid, linezolid |
| Expanded regimen terminology |
BPaLM adds moxifloxacin |
| U.S. commercial company |
Viatris, following its acquisition of Mylan |
| Original development platform |
TB Alliance |
| Regulatory pathway |
FDA new drug application |
| Biosimilar relevance |
None; pretomanid is a small-molecule drug |
The principal commercial distinction is that pretomanid is a regimen-enabling product rather than a broad primary-care or chronic-disease medicine. Its utilization follows national tuberculosis programs, specialist centers, donor procurement, and resistance surveillance.
How large is the pretomanid market?
The addressable market is the population with rifampicin-resistant, multidrug-resistant, extensively drug-resistant, or treatment-intolerant pulmonary tuberculosis that qualifies for a shortened all-oral regimen. That population is materially smaller than the global tuberculosis market.
The World Health Organization estimated approximately 400,000 people developed multidrug-resistant or rifampicin-resistant TB in 2022, with a smaller subset meeting criteria for the most intensive pretomanid-containing regimens. Treatment access remains below epidemiological need because of underdiagnosis, limited drug-susceptibility testing, health-system capacity, and financing gaps. [3]
Pretomanid’s market has four demand segments:
- U.S. and other high-income-country specialty treatment.
- National TB programs in countries with high drug-resistant TB burdens.
- Global Fund and Stop TB Partnership procurement.
- Humanitarian and donor-supported treatment programs.
The highest-volume opportunity is outside the United States. The United States is commercially important for regulatory validation and pricing, but its patient volume is low relative to India, China, Russia, Indonesia, South Africa, and other countries with substantial drug-resistant TB burdens.
What is the financial trajectory for pretomanid?
Pretomanid revenue is not separately reported in Viatris’ public financial statements. Viatris reports broad product and geographic categories rather than Dovprela sales as a standalone line item. The product is therefore best assessed through market access, regimen uptake, procurement volumes, and pricing rather than reported quarterly revenue.
Financial trajectory by phase
| Period |
Commercial and financial development |
| Before 2019 |
Development-stage asset with no product revenue |
| 2019 |
FDA approval created U.S. commercial eligibility |
| 2020 |
Mylan became the relevant commercial platform through its combination with Upjohn |
| 2020-2022 |
Global rollout depended on regulatory approvals, national guidelines, and public procurement |
| 2022 |
WHO recommended a six-month BPaLM regimen for eligible drug-resistant TB patients |
| 2023-2024 |
Demand potential improved as shorter all-oral regimens entered treatment guidelines |
| Longer term |
Revenue remains volume-constrained and procurement-dependent |
The most important financial catalyst is regimen expansion. WHO recommendations in 2022 supported a six-month BPaLM regimen for eligible patients, replacing longer and more toxic treatment approaches in appropriate settings. That change can increase pretomanid utilization because the drug moves from a narrow salvage option toward a standardized regimen component. [3]
The principal financial constraints are low treatment volumes, public-sector price pressure, and the absence of a large private-pay market. Pretomanid is unlikely to become a material contributor to Viatris group revenue without a significant increase in diagnosed and treated drug-resistant TB cases.
How does pretomanid generate commercial value if standalone revenue is limited?
Pretomanid creates value through regimen economics rather than standalone prescription volume. A shorter treatment course can reduce hospitalization, monitoring, toxicity management, adherence failure, and indirect costs. These benefits support adoption even when the individual drug price is controlled.
The commercial value proposition includes:
- A shorter all-oral treatment option.
- Reduced reliance on injectable agents.
- Use in patients with limited alternatives.
- Potentially lower total treatment cost.
- Integration into global treatment guidelines.
- Eligibility for donor and public-sector procurement.
The value is shared across the BPaL or BPaLM combination. Bedaquiline remains a central regimen component, while linezolid contributes substantial efficacy but also creates toxicity and monitoring concerns. Pretomanid’s commercial position is strongest when treatment programs want to replace longer injectable regimens with shorter oral therapy.
What is the FDA regulatory status of Dovprela?
Dovprela has full FDA approval for its labeled combination use. The label contains important safety and administration restrictions, including warnings associated with myelosuppression, peripheral and optic neuropathy, hepatotoxicity, QT-related considerations, and reproductive risks. Linezolid toxicity is a major component of the overall regimen-monitoring burden. [1]
The FDA approval does not establish broad use for ordinary drug-susceptible TB. It applies to a defined resistant-TB population. Off-label expansion beyond the approved population depends on clinical evidence, treatment guidelines, and physician judgment.
FDA exclusivity
Pretomanid received new chemical entity exclusivity associated with its 2019 approval. The five-year NCE period would generally run from approval, subject to statutory adjustments and any applicable pediatric exclusivity. That period did not create a long commercial runway relative to the drug’s development history.
The economic importance of FDA exclusivity was lower than it would be for a mass-market drug because the product’s sales depend on a narrow indication. The principal commercial defenses are likely to come from formulation, manufacturing, regulatory complexity, and procurement relationships rather than from a long period of high-volume U.S. exclusivity.
What patents protect pretomanid?
Pretomanid originated from TB Alliance’s drug-development program and earlier nitroimidazole patent work. The relevant intellectual-property position has historically included compound, process, formulation, and use-related rights. Patent protection varies by country and depends on filing dates, national prosecution, patent-term adjustments, terminal disclaimers, and extensions.
The core commercial issue is patent maturity. Pretomanid was discovered decades before FDA approval, so original compound patent rights had substantially aged by the time Dovprela reached the market. Later patents may cover specific formulations, combinations, manufacturing processes, or therapeutic uses, but those rights do not necessarily block every generic pretomanid product.
A practical IP assessment should distinguish:
| IP category |
Commercial effect |
| Compound patents |
Potentially broad but often earliest-expiring rights |
| Salt or crystal-form patents |
May protect a defined solid form |
| Formulation patents |
Can delay substitution for a specific dosage form |
| Combination patents |
May cover BPaL or related regimens |
| Method-of-use patents |
May target resistant-TB treatment populations |
| Manufacturing patents |
Can increase development and scale-up costs |
| Regulatory exclusivity |
Separate from patent protection and time-limited |
The FDA Orange Book should be reviewed for current patent listings associated with NDA 212862 before making a U.S. Paragraph IV or launch assessment. Public company filings do not provide a separate, comprehensive pretomanid patent schedule. [1, 4]
When does pretomanid lose exclusivity?
Pretomanid’s earliest regulatory exclusivity began expiring after the 2019 FDA approval period, while patent expiry depends on the specific patent family and country. There is no single global pretomanid exclusivity date.
For U.S. generic entry, the relevant sequence is:
- FDA regulatory exclusivity expiration.
- Expiration or successful challenge of any listed Orange Book patents.
- ANDA filing and Paragraph IV certification, if applicable.
- Patent litigation under the Hatch-Waxman framework.
- FDA approval and commercial launch.
Because Dovprela has a narrow market, generic entrants may have less incentive to litigate early than they would for a high-revenue cardiovascular, diabetes, or oncology product. A generic company may wait for clearer procurement demand or launch after relevant barriers fall.
Are there Paragraph IV challenges to Dovprela?
No major publicly reported Paragraph IV litigation has become a defining commercial event for Dovprela in the available public record. That does not establish that no ANDA certifications or confidential patent disputes exist. Paragraph IV risk should be evaluated against the current Orange Book record, FDA ANDA activity, and federal court dockets.
The litigation incentive is limited by:
- Small U.S. patient volume.
- Public and institutional purchasing.
- Combination-regimen dependence.
- Potentially modest standalone revenue.
- Manufacturing and quality requirements for a specialized anti-infective.
- Uncertain pricing after generic entry.
A successful generic would not necessarily replace all pretomanid demand. National TB programs may continue buying the branded or authorized product if it has established supply reliability, procurement qualification, or favorable donor pricing.
What is the Orange Book status of Dovprela?
Dovprela is listed by the FDA as an approved prescription product under NDA 212862. The commercial significance of any Orange Book patent listing depends on whether the listed patent covers the active ingredient, a formulation, a method of use, or another legally relevant feature.
For Dovprela, the most important distinction is between approval status and effective market protection. FDA approval confirms that a product may be marketed for the labeled indication. It does not by itself establish a long patent term or prevent all alternative pretomanid products.
A generic applicant could pursue an ANDA with:
- Paragraph III certification, agreeing to wait for patent expiry.
- Paragraph IV certification, challenging listed patents.
- A section viii statement, carving out patented methods of use where legally available.
- A separate 505(b)(2) strategy if the proposed product relies on a different formulation or indication.
Which companies are challenging or competing with pretomanid?
Pretomanid competes less against a single branded product than against alternative drug-resistant TB regimens.
| Competitor or alternative |
Role in the market |
| Bedaquiline |
Essential companion drug and major regimen anchor |
| Linezolid |
Core BPaL component; effective but toxicity-limited |
| Moxifloxacin |
Added in BPaLM for eligible patients |
| Delamanid |
Alternative nitroimidazole-class therapy |
| Clofazimine |
Used in longer or alternative resistant-TB regimens |
| Cycloserine or terizidone |
Options in selected longer regimens |
| Injectable agents |
Reduced role as all-oral regimens expand |
| Generic pretomanid |
Potential future price competitor |
Pretomanid’s closest clinical comparison is delamanid, another nitroimidazole-class TB drug. Delamanid has a different regulatory history and regimen role. BPaL and BPaLM also compete with shorter regimens that may omit pretomanid when patients meet eligibility criteria for alternative treatment strategies.
What licensing deals affect pretomanid commercialization?
TB Alliance developed pretomanid through a nonprofit product-development model and licensed commercialization rights to Mylan. Mylan became part of Viatris in 2020. The licensing structure enabled the product to reach FDA approval while preserving a public-health focus on access in drug-resistant TB markets. [2, 4]
Commercial rights are geographically segmented and may involve different partners, registration holders, distributors, or public procurement channels. The existence of a global development license does not mean that one company controls every market or every formulation.
The key economic implications are:
- Viatris has a commercial platform but does not control the entire global TB ecosystem.
- TB Alliance retains an important role in access strategy and product development.
- Public-sector pricing limits margin expansion.
- Procurement commitments can matter more than retail prescribing.
- Geographic licensing can create different prices and launch timing by country.
What geographic markets offer the greatest growth?
India and other high-burden countries offer the largest volume opportunity, but they also present the strongest pricing pressure and the most complex regulatory and procurement conditions. The United States offers higher unit economics but limited patient numbers.
Geographic opportunity profile
| Market |
Opportunity |
Constraint |
| United States |
Higher price and regulatory reference value |
Small patient population |
| India |
Large resistant-TB burden and manufacturing capacity |
Low public-sector pricing and local competition |
| South Africa |
Strong guideline and donor relevance |
Procurement concentration |
| Southeast Asia |
Significant TB burden |
Variable diagnosis and registration |
| Europe |
Specialist demand and public-health value |
Small eligible population |
| China and Russia |
Epidemiological relevance |
Regulatory, commercial, and access complexity |
| Donor-funded markets |
Volume and public-health impact |
Price ceilings and tender dependence |
Global guideline adoption is more important than conventional physician marketing. National programs must diagnose resistance, procure all regimen components, train clinicians, and monitor adverse events before pretomanid demand can scale.
What manufacturing and IP barriers affect generic entry?
Pretomanid tablets are simpler to manufacture than biologics, but generic entry still requires validated active pharmaceutical ingredient supply, impurity control, stability data, bioequivalence, and regulatory approval. The drug is used in a safety-sensitive combination regimen, so quality failures can have clinical and public-health consequences.
Manufacturing barriers include:
- Limited API suppliers with experience in nitroimidazole chemistry.
- Requirements for consistent impurity profiles.
- Small global demand relative to commercial manufacturing scale.
- Country-specific registration and serialization rules.
- Need to coordinate supply with bedaquiline and linezolid.
- Tender qualification and pharmacovigilance obligations.
These barriers can preserve the incumbent’s position after basic compound protection expires. They are not absolute barriers. A technically capable generic manufacturer with public-sector procurement access could enter if expected volumes support regulatory and manufacturing investment.
What generic launch scenarios exist for pretomanid?
Scenario 1: No near-term U.S. generic launch
This is the most commercially plausible outcome if the U.S. market remains small and litigation economics are unattractive. Viatris would retain brand supply, while international procurement would determine most volume.
Scenario 2: Authorized or licensed generic
A licensed generic could expand access without a confrontational patent challenge. This approach would align with public-health procurement and could protect the originator’s role in quality assurance and supply management.
Scenario 3: Independent generic launch
An independent generic becomes more likely if demand rises through BPaLM adoption, patent barriers weaken, and large TB manufacturers seek donor-funded volume. Price erosion would be greatest in tenders rather than U.S. specialty channels.
Scenario 4: Combination-regimen competition
Even without a pretomanid generic, competition could reduce demand if shorter regimens or alternative combinations become preferred by WHO or national programs.
How strong is the pretomanid commercial position?
Pretomanid has high clinical differentiation in a narrow indication and moderate commercial defensibility.
| Factor |
Assessment |
| Clinical need |
High |
| Eligible population |
Limited |
| Regulatory status |
Strong: FDA-approved |
| Standalone prescribing |
Weak because combination use is mandatory |
| Public-sector demand |
Potentially strong |
| Pricing power |
Limited |
| Patent durability |
Constrained by long development timeline |
| Manufacturing complexity |
Moderate |
| Generic incentive |
Moderate to low in the United States |
| Guideline sensitivity |
Very high |
| Revenue visibility |
Low because sales are not separately disclosed |
Its strongest asset is inclusion in internationally recognized shorter regimens. Its weakest feature is the mismatch between high clinical importance and limited commercial scale.
What patent litigation affects pretomanid?
No major public patent litigation has materially altered the Dovprela market trajectory in the available record. The relevant legal risks are prospective:
- ANDA Paragraph IV challenges.
- Patent litigation over listed formulation or use claims.
- Patent disputes involving combination regimens.
- Compulsory licensing or government-use actions in high-burden countries.
- Procurement challenges over access pricing.
- Regulatory disputes involving local generic registrations.
For investors and licensing teams, the key legal question is not only whether a patent survives. It is whether the surviving claim covers the commercially relevant product, regimen, or manufacturing route.
Key Takeaways
- Pretomanid is an FDA-approved component of BPaL, not a standalone TB treatment.
- Dovprela was approved in August 2019 under NDA 212862.
- Viatris acquired the commercial platform through its acquisition of Mylan.
- Pretomanid revenue is not separately disclosed, so product-level financial performance cannot be calculated from public Viatris reporting.
- Growth depends primarily on WHO and national adoption of shorter all-oral drug-resistant TB regimens.
- The largest volume opportunity is in high-burden and donor-funded markets, not the United States.
- Public procurement and access pricing will limit gross-margin expansion.
- Patent age reduces the value of the original compound estate; formulation, use, process, and regulatory barriers may matter more.
- No major publicly reported Paragraph IV litigation has defined the product’s current market.
- Generic entry is commercially possible but may be delayed by low U.S. volumes, procurement complexity, and manufacturing economics.
- The product’s value is tied to the BPaL and BPaLM regimens, making guideline changes the principal demand risk.
FAQs About Pretomanid Market and Exclusivity
Is pretomanid a blockbuster drug?
No. Its eligible population is small, and public-sector pricing and combination use limit standalone revenue potential.
Who owns Dovprela?
Viatris commercializes Dovprela in the United States following its acquisition of Mylan. TB Alliance remains central to the product’s development and licensing structure.
Can pretomanid be used alone?
No. The FDA-approved use requires combination treatment with bedaquiline and linezolid.
Is pretomanid a biologic or a small-molecule drug?
Pretomanid is a synthetic small-molecule antibacterial. Biosimilar rules do not apply.
What would most increase pretomanid sales?
The largest potential driver is broader implementation of WHO-recommended shorter BPaL or BPaLM regimens, supported by improved drug-resistance diagnosis and public procurement funding.
References
-
U.S. Food and Drug Administration. (2019). Dovprela: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212862s000lbl.pdf
-
TB Alliance. (2019). FDA approves new treatment for highly drug-resistant forms of tuberculosis. https://www.tballiance.org
-
World Health Organization. (2022). WHO consolidated guidelines on tuberculosis: Module 4: Treatment - Drug-resistant tuberculosis treatment. World Health Organization. https://www.who.int/publications/i/item/9789240063129
-
Viatris Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. https://investor.viatris.com/financial-information/annual-reports-and-proxy-statements
